MENU
NVO
Stock ticker: NYSE
PRICE
CHANGE
CAPITALIZATION

Novo-Nordisk A/S (NVO) Earnings Date & Reports

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products... Show more

A.I. Advisor
published Earnings

NVO is expected to report earnings to fall 22.52% to 68 cents per share on February 03

Novo-Nordisk A/S NVO Stock Earnings Reports
Q4'26
Est.
$0.69
Q3'26
Beat
by $0.08
Q2'26
Beat
by $0.17
Q1'26
Missed
by $0.05
Q4'25
Beat
by $0.10
The last earnings report on November 04 showed earnings per share of 88 cents, beating the estimate of 81 cents. With 16.66M shares outstanding, the current market capitalization sits at 178.04B.
A.I.Advisor
Nov 04, 2026

Novo Nordisk (NVO) Q3 2026 Earnings Recap: Obesity Demand Fuels a Guidance Boost

Key Takeaways

  • Novo Nordisk reported third-quarter 2026 adjusted net sales of DKK 79.2 billion, up 4% at constant exchange rates (CER), beating consensus estimates of roughly DKK 73.6 billion.
  • Adjusted earnings per share (EPS) came in at DKK 5.79, down 12% year over year but above the Wall Street consensus of DKK 4.80.
  • Obesity care sales rose 22% at constant exchange rates to DKK 26.15 billion, driven by strong GLP-1 volume growth, including the new Wegovy pill.
  • Reported operating profit fell 9% at constant exchange rates to DKK 23.01 billion, weighed down by DKK 8.7 billion in non-cash impairment charges.
  • The company raised its full-year 2026 outlook, now expecting adjusted sales and operating profit growth of -2% to +2% at constant exchange rates, up from a prior range of -6% to 0%.
  • Shares climbed more than 5% in pre-market trading following the announcement.
  • For more context on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, visit the dedicated ticker pages.
  • Explore Trending AI Robots to see AI-powered trading strategies currently gaining traction in the market.

Earnings Context and Why It Matters

Novo Nordisk's third-quarter 2026 results arrived at a pivotal moment for the Danish pharmaceutical giant. After a turbulent stretch in which it ceded momentum to rival Eli Lilly in the fiercely competitive obesity and diabetes market, investors were watching closely for signs of a durable turnaround. The company's GLP-1 (glucagon-like peptide-1) franchise, anchored by Wegovy and Ozempic, remains central to its growth story, while the newly launched Wegovy pill represents its next major commercial test. With the stock having underperformed through much of 2025 and early 2026, this report served as a key gauge of whether improving patient volumes and pipeline momentum could restore confidence in the company's long-term trajectory.

Reported Results

For the third quarter ended September 30, 2026, Novo Nordisk reported adjusted net sales of DKK 79.2 billion (Danish kroner), an increase of 6% in reported terms and 4% at constant exchange rates. That result exceeded the consensus estimate of approximately DKK 73.6 billion. Adjusted operating profit rose 27% at constant exchange rates to DKK 31.72 billion, also ahead of expectations.

Adjusted earnings per share came in at DKK 5.79, a 12% decline from the prior-year period but comfortably above the DKK 4.80 analysts had projected. Adjusted net profit totaled DKK 25.60 billion, down 12% year over year yet above the DKK 20.54 billion consensus.

On a reported basis, however, operating profit declined 9% at constant exchange rates to DKK 23.01 billion. The gap reflected DKK 8.7 billion in non-cash impairment charges, including a DKK 4.6 billion write-down tied to the investigational drug ziltivekimab and DKK 4.1 billion in charges related to restructuring of the company's manufacturing network.

Obesity care was the standout segment, with sales rising 22% at constant exchange rates to DKK 26.15 billion. The new Wegovy pill generated roughly DKK 5.4 billion in sales during the quarter. On the guidance front, Novo Nordisk raised its full-year 2026 outlook, now projecting adjusted sales and operating profit growth of -2% to +2% at constant exchange rates, an improvement from its previous -6% to 0% range, alongside expected free cash flow of DKK 60 billion to DKK 70 billion.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters covering industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a practical resource for identifying setups aligned with your strategy. Consider exploring the AI Screener to uncover new opportunities in sectors such as healthcare and pharmaceuticals.

Market Reaction and Investor Sentiment

The market responded favorably to the results, with Novo Nordisk's American depositary receipts climbing more than 5% in pre-market trading. Investors appeared to reward both the top- and bottom-line beats and, more importantly, the upward revision to full-year guidance, which signaled that management sees the business returning to a more stable footing. The strength of obesity care, particularly the rapid uptake of the Wegovy pill, helped ease concerns about the company's ability to compete in an increasingly crowded GLP-1 market. At the same time, the sizable impairment charges served as a reminder that the company's push to rationalize its manufacturing network and refocus its pipeline carries near-term costs, even as the underlying commercial performance improves.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be tracking several themes as Novo Nordisk moves toward full-year 2026 and into 2027. The most closely watched catalyst is the planned U.S. launch of CagriSema, its next-generation obesity treatment, expected in early 2027 subject to regulatory approval. Success there could materially reshape the competitive landscape against Eli Lilly.

Pricing dynamics also warrant attention. The company has said it plans to cut the U.S. wholesale acquisition cost of Wegovy by about 50% and Ozempic by about 35%, bringing both to $675 beginning January 1, 2027. While these reductions aim to broaden patient access, they could pressure realized prices and revenue growth in the near term.

Finally, watch for continued execution on the Wegovy pill rollout across international markets, ongoing patient volume trends in both obesity and diabetes, and any further updates on manufacturing network restructuring costs. These factors will be central to determining whether the company's improved guidance can be sustained through the remainder of the year and beyond.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations